Briefing Calendar IPOs Opportunities Companies Compare Analytics Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

VEC-162 20 mg - Phase 3 | VNDA Pipeline | CatalystAlert

VEC-162 20 mg

Phase 3

Vanda Pharmaceuticals Inc. (VNDA)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Primary Insomnia

Clinical Trial

Last updated: 1/2/2026

Developer

VNDA

Vanda Pharmaceuticals Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Tasimelteon Oral Capsule, Tasimelteon Liquid SuspensionPhase 3

Autism Spectrum Disorder

20 mg VEC-162Phase 3

Insomnia

Tasimelteon Oral SuspensionPhase 3

Insomnia Disorder

TradipitantPhase 3

Motion Sickness

ZiprasidonePhase 3

Schizophrenia

View full pipeline